Louise Chen
Stock Analyst at Scotiabank
(3.16)
# 1,197
Out of 5,008 analysts
300
Total ratings
46.69%
Success rate
0.94%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $23.26 | +243.94% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.90 | +373.68% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $15.35 | -8.79% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.22 | +440.54% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $17.42 | +215.73% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $64.81 | -15.14% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.55 | +322.54% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $67.95 | -26.42% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.20 | +188.46% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $15.90 | +6.92% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $46.18 | +51.58% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $12.65 | +295.26% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $10.27 | +192.11% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $33.31 | +65.12% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.09 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $59.65 | +168.23% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $41.21 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $230.19 | +4.26% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.43 | +70.26% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $188.16 | +14.26% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.65 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $88.80 | +74.55% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.26 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $845.05 | +4.73% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.43 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.55 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.32 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.09 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $96.45 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.75 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.33 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.96 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $585.48 | +57.99% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.79 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.18 | +1,944.03% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.60 | +212.50% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $4.35 | +474.71% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.22 | +208.26% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $19.76 | +153.04% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.05 | +376.19% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.36 | +2,397.92% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.19 | +77,054,694.52% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $275.01 | -6.19% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $19.96 | -24.85% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.34 | +3,631.34% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.58 | +1,165.82% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.29 | +517.28% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $23.26
Upside: +243.94%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.90
Upside: +373.68%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $15.35
Upside: -8.79%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.22
Upside: +440.54%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $17.42
Upside: +215.73%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $64.81
Upside: -15.14%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.55
Upside: +322.54%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $67.95
Upside: -26.42%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.20
Upside: +188.46%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $15.90
Upside: +6.92%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $46.18
Upside: +51.58%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $12.65
Upside: +295.26%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $10.27
Upside: +192.11%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $33.31
Upside: +65.12%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.09
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $59.65
Upside: +168.23%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $41.21
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $230.19
Upside: +4.26%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.43
Upside: +70.26%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $188.16
Upside: +14.26%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.65
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $88.80
Upside: +74.55%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.26
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $845.05
Upside: +4.73%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.55
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.32
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.09
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $96.45
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.75
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.33
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $585.48
Upside: +57.99%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.79
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.18
Upside: +1,944.03%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.60
Upside: +212.50%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $4.35
Upside: +474.71%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.22
Upside: +208.26%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $19.76
Upside: +153.04%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.05
Upside: +376.19%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.36
Upside: +2,397.92%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.19
Upside: +77,054,694.52%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $275.01
Upside: -6.19%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $19.96
Upside: -24.85%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.34
Upside: +3,631.34%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.58
Upside: +1,165.82%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.29
Upside: +517.28%